Tecnologico de Monterrey, 27746School of Medicine and Health Sciences, Monterrey, México.
Instituto de Cardiología y Medicina Vascular, TecSalud, San Pedro Garza García, México.
Vascular. 2022 Dec;30(6):1107-1114. doi: 10.1177/17085381211052033. Epub 2021 Dec 4.
Few studies have focused on arterial thrombosis and acute limb ischemia in COVID-19. This international registry intended to study the spectrum of clinical characteristics, therapeutic trends, and outcomes in a cohort of Ibero-Latin American patients with arterial thrombosis or acute limb ischemia and COVID-19.
Data were retrospectively obtained from 21 centers in 9 countries. Patients with proven COVID-19 and asymptomatic or symptomatic arterial thrombosis were included. COVID-19 diagnosis was established by RT-PCR assay or IgM serology plus suggestive clinical/radiographical findings. We recorded and analyzed variables related to demography, clinical presentation, therapeutic trends, and outcomes.
Eighty one patients were included in the registry. In 38.3%, acute limb ischemia symptoms were the first manifestation of COVID-19. Non-surgical management was more frequent in severe cases than surgical interventions, 11.1% vs. 88.9%, respectively ( = 0.004). Amputation rates were similar between all COVID severity groups ( = 0.807). Treatment was classified as non-surgical, open surgical, and endovascular treatment. Further analysis revealed an equal frequency of major leg amputation between treatment groups and increased mortality in patients with non-surgical management. However, multivariate regression analysis showed that treatment choices are associated with disease severity, with significant non-surgical treatment in critical patients; thus, mortality is related to the severity and confounds treatment analysis.
Arterial thrombosis can be the initial symptom of a patient presenting with COVID-19. Physicians and health workers should potentially suspect COVID-19 in acute ischemia cases without a known risk factor or embolic cause. More experimental and clinical research is required to understand the complex phenomenon of arterial COVID-19 induced coagulopathy fully.
鲜有研究关注 COVID-19 患者中的动脉血栓形成和急性肢体缺血。本国际登记研究旨在分析一组来自伊比利亚-拉丁美洲的动脉血栓形成或急性肢体缺血合并 COVID-19 患者的临床特征、治疗趋势和结局。
数据来自 9 个国家的 21 个中心,回顾性获取。纳入确诊 COVID-19 且存在无症状或有症状动脉血栓形成的患者。COVID-19 诊断通过 RT-PCR 检测或 IgM 血清学加提示性临床/影像学发现确定。我们记录并分析了与人口统计学、临床表现、治疗趋势和结局相关的变量。
登记研究共纳入 81 例患者,38.3%的患者急性肢体缺血症状是 COVID-19 的首发表现。严重病例较手术干预更倾向于非手术治疗,分别为 11.1%和 88.9%( = 0.004)。所有 COVID 严重程度组的截肢率相似( = 0.807)。治疗分类为非手术、开放手术和血管内治疗。进一步分析显示,治疗组之间主要腿部截肢的发生率相同,非手术治疗患者的死亡率更高。然而,多变量回归分析表明,治疗选择与疾病严重程度相关,危重症患者更倾向于非手术治疗,因此死亡率与严重程度相关,且会影响治疗分析。
动脉血栓形成可能是 COVID-19 患者的首发症状。对于无已知危险因素或栓塞原因的急性缺血患者,医生和卫生工作者应考虑到 COVID-19 的可能性。需要更多的实验和临床研究来充分了解动脉 COVID-19 诱导的凝血功能障碍这一复杂现象。